ANGES MOVES FORWARD WITH PHASE I TRIAL FOR HGF GENE MEDICINE

AnGes has registered the ninth case of its Phase I clinical trials of HGF (hepatocyte growth factor) gene medicine conducted in the U.S. The company has been conducting the Phase I clinical trials, intended for the treatment of ischemic heart disease, since November 2004.

In Japan, AnGes is currently proceeding with Phase III clinical trials of HGF gene medicine, intended for the treatment of peripheral arterial disease.